An Open-Label, Single-arm, Phase I Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2015
At a glance
- Drugs Sotrastaurin (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Novartis
- 11 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 30 Jan 2014 Status changed from recruiting to discontinued, as reported by M.D. Anderson Cancer Center record.
- 17 May 2013 Planned end date changed from 1 Jan 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.